New Zealand markets close in 2 hours 22 minutes

BIIB Jan 2023 125.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
264.000.00 (0.00%)
As of 07:46AM EDT. Market open.
Full screen
Previous close264.00
Open264.00
Bid108.00
Ask117.10
Strike125.00
Expiry date2023-01-20
Day's range264.00 - 264.00
Contract rangeN/A
Volume2
Open interest3
  • Financial Times

    Alzheimer’s drug trial brings pivotal test of maligned brain plaque theory

    A late-stage trial of an Alzheimer’s drug set to generate results within weeks is shaping up as a pivotal moment in a three-decade quest to prove that removing sticky amyloid plaques from the brain can slow down the disease. The phase 3 trial is being led by Eisai, a Tokyo-based pharmaceutical company that has partnered US biotech Biogen to develop lecanemab. Earlier studies suggested the monoclonal antibody treatment can clear plaques known as beta amyloid that are at the centre of an increasingly acrimonious scientific debate over what causes Alzheimer’s.

  • GlobeNewswire

    The New England Journal of Medicine Publishes Pivotal Tofersen Data that Show Benefits in Rare, Genetic Form of ALS

    Publication includes the Phase 3 VALOR SOD1-ALS trial and its open-label-extension study, underscoring the importance of these longer-term data12-month data show earlier initiation of tofersen slowed decline across critical measures of function and strength in people diagnosed with SOD1-ALSResults offer important learnings regarding the biology of SOD1-ALS and design of ALS clinical trials CAMBRIDGE, Mass., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that The Ne

  • Financial Times

    Biogen drug slows progress of motor neurone disease in landmark trial

    Tofersen targets a defective gene that causes about 2% of cases of MND, also known as amyotrophic lateral sclerosis